Novadiscovery, a healthtech company offering the clinical trial simulation platform, Jinkō, to predict drug efficacy and optimize clinical trial development, has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline.
Novadiscovery is committed to working with forward-looking industry leaders to improve R&D productivity and maximize patient outcomes through disease modelling and simulation, ahead of human trials.
Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve clinical trial efficiency and increase the probability of regulatory success.
François-Henri Boissel, CEO, Novadiscovery, commented: “We are proud to have been selected by a leading pharmaceutical company to help provide answers to key clinical development questions in the future of healthcare. We are excited to join with Janssen France as it adopts this new technology and we envisage a long and productive collaboration.”
Philippe Bonnard, Medical Director Oncology, Janssen France, highlighted: “Our strategic goal is to transform drug R&D using innovative digital technologies. In this collaboration with Nova, we look forward to realising the potential of in silico technology to help us deliver higher quality compounds more effectively.”
Image credit: Scott Graham
